Refine
Year of publication
Document Type
- Article (106)
- Preprint (12)
- Conference Proceeding (5)
- Book (3)
Has Fulltext
- yes (126)
Is part of the Bibliography
- no (126)
Keywords
- Mammakarzinom (12)
- breast cancer (12)
- Behandlung (8)
- Metastasen (8)
- CDK4/6 (6)
- PD1/PDL1 (6)
- Prävention (6)
- Studien (6)
- prevention (6)
- treatment (6)
- metastases (5)
- Risiko (4)
- risk (4)
- trials (4)
- metastatic (3)
- Alpelisib (2)
- Atezolizumab (2)
- Biomarkers (2)
- CV9202 (2)
- Diagnostik (2)
- Früherkennung (2)
- Healthy adults (2)
- Katherine (2)
- Lokalrezidiv (2)
- NMR spectroscopy (2)
- Nachsorge (2)
- Non-small cell lung cancer (2)
- PARP (2)
- PD1/ PDL1 (2)
- PD‑L1 (2)
- PI3K (2)
- Phylogeographie (2)
- Prognosefaktoren (2)
- Prädiktivfaktoren (2)
- Richtlinie (2)
- Supportivtherapie (2)
- T‑DM1 (2)
- adjuvant therapy (2)
- adjuvante Therapie (2)
- advanced (2)
- alpelisib (2)
- atezolizumab (2)
- diagnosis (2)
- early breast cancer (2)
- follow‑up (2)
- fortgeschritten (2)
- frühes Mammakarzinom (2)
- guideline (2)
- kidney (2)
- local recurrence (2)
- neoadjuvant therapy (2)
- neoadjuvante Therapie (2)
- phylogeography (2)
- predictive factors (2)
- prognostic factors (2)
- screening (2)
- studies (2)
- supportive therapy (2)
- survival (2)
- treatment/therapy (2)
- 1,2-Dimesitoylbenzene (1)
- ADAMTS-13 (1)
- AM1 Calculations (1)
- AML (1)
- Advanced breast cancer (1)
- Alzheimer’s dementia (1)
- Amyloid-beta 42 (1)
- Animal models (1)
- Anti-kaon–nucleon physics (1)
- Antihormone therapy (1)
- Automata theory (1)
- BCOR (1)
- BCORL1 (1)
- BI1361849 (1)
- Baryonic resonances (1)
- Benthos (1)
- Biodiversität (1)
- Biotin (1)
- Blocked occlusion (1)
- Body sway (1)
- CAI-1 (1)
- CRISPR/Cas (1)
- Carrier-bound fibrin sealant (1)
- Causality assessment (1)
- Clinical Trials and Observations (1)
- Clinical trial (1)
- Cohort studies (1)
- Collagen hemostat (1)
- Council for International Organizations of Medical Sciences (1)
- Crystal Structure (1)
- Crystal structure (1)
- Cyanine Distortion (1)
- Dehydrogenase Cofactors (1)
- Direct carbon (1)
- Diversity (1)
- Duganella (1)
- EP300 (1)
- ESR Spectra (1)
- EWSR1 (1)
- Effective half-life (1)
- Electron Transfer (1)
- Electron-pion identification (1)
- Electronic Structure (1)
- Entomology (1)
- Esters (1)
- Eukaryota (1)
- Expedition Brochure (1)
- Expeditionsbericht (1)
- FAPI PET (1)
- FOXO1 (1)
- Fibre/foam sandwich radiator (1)
- Freezeout (1)
- Fusarium graminearum (1)
- G-protein-coupled receptor (1)
- Gene fusion (1)
- Genome editing (1)
- Graves’ disease (1)
- HER2 c-erbB2 (1)
- HER2/neu (1)
- Heavy ion storage ring (1)
- Heavy-ion reactions (1)
- Hemostatics (1)
- Herb induced liver injury (1)
- Herbs (1)
- Heregulin (1)
- High-pressure (1)
- Hippocampal volume (1)
- Hyperconjugation (1)
- Hypofractionated radiotherapy (1)
- Immunomonitoring (1)
- Infinite games with perfect information (1)
- Internal ribosome entry site (1)
- Ionisation energy loss (1)
- Isolierung (1)
- Janthinobacterium (1)
- Kaonic nuclei (1)
- Labordiagnose (1)
- Lebensgemeinschaft (1)
- Liver resection (1)
- Low energy QCD (1)
- Luciferase (1)
- MM-121 (1)
- MNDO Calculations (1)
- Meersseman test (1)
- Meloneta alpica (1)
- Metastatic (1)
- Mild cognitive impairment (1)
- Molecular Conformation (1)
- Molecular diagnostic testing (1)
- Multi-wire proportional drift chamber (1)
- Multianvil (1)
- Myeloid Neoplasia (1)
- Neural network (1)
- Neuroepithelial tumor (1)
- Orbital electron capture (1)
- Organosilicon Compounds (1)
- Orthopaedics (1)
- Oxidation States (1)
- Oxo-and Alkylamino-Substituted p-Benzoquinone Derivatives (1)
- PAGE (1)
- PCR (1)
- PLAGL1 (1)
- Partial wave analysis (1)
- Phospho-tau (1)
- Phosphorylation (1)
- Phylogenetik (1)
- Phylogenomics (1)
- Pityogenes (1)
- Population genetics (1)
- Prediction (1)
- Protein translation (1)
- RNA (1)
- RNActive (1)
- Radical Anion Sodium Salt (1)
- Radioiodine therapy (1)
- Radioiodine uptake test (1)
- Randomized controlled trial (1)
- Rare-earth borate (1)
- Re-exposure (1)
- Registries (1)
- Ruthenium Complexes (1)
- SSCP (1)
- Scolytidae (1)
- Scolytinae (1)
- Seribantumab (1)
- Single Crystal Structures (1)
- Single particle decay spectroscopy (1)
- Substituent Effects (1)
- Supratentorial (1)
- Symmetrical blocked occlusion (1)
- T-DM1 (1)
- TLR2/6 (1)
- TR (1)
- Tau (1)
- Terbium (1)
- Thyroid (1)
- Tracking (1)
- Transition radiation detector (1)
- Translation initiation (1)
- Translational research (1)
- Trigger (1)
- Two body weak decay (1)
- Upper body posture (1)
- VARGADO (1)
- Videorasterstereography (1)
- Water balance (1)
- Weight distribution (1)
- Xenon-based gas mixture (1)
- Zellkultur (1)
- Zooplankton (1)
- acute myeloid leukemia (1)
- advanced breast cancer (1)
- algorithms (1)
- allocation (1)
- angio-immunogenic switch (1)
- antihormone therapy (1)
- available water capacity (1)
- bacterium-fungus interaction (1)
- benthic communities (1)
- biodiversity (1)
- biogenic amine (1)
- bleeding (1)
- blood flow recovery (1)
- bortezomib (1)
- cell culture (1)
- cellular signaling (1)
- chemical vapour deposition (1)
- chemotherapy (1)
- child (1)
- collateral growth (1)
- combinatorics (1)
- dE/dx (1)
- data structures (1)
- denervation (1)
- detection (1)
- docetaxel (1)
- dopamine (1)
- drought-stress (1)
- dwarf-shrub heath (1)
- femoral artery ligation (1)
- fibrosis imaging (1)
- field-effect transistor (1)
- forest (1)
- forest site classification (1)
- fourth (1)
- graft (1)
- habitat boundary (1)
- hierarchies and reducibilities (1)
- induction chemotherapy (1)
- induction regimen (1)
- insect (1)
- interleukin-6 (1)
- intracranial hemorrhage (1)
- isolation (1)
- laboratory diagnosis (1)
- lapatinib (1)
- lenalidomide (1)
- local radiotherapy (1)
- logic (1)
- loss (1)
- loss-of-function (1)
- mRNA active cancer immunotherapy (1)
- mRNA vaccine (1)
- metastasis (1)
- mitochondrial DNA (1)
- mitochondriale DNA (1)
- mtDNA (1)
- multiple myeloma (1)
- nintedanib (1)
- non-small cell lung cancer (1)
- non-small-cell lung cancer (1)
- nuclear cardiology (1)
- oligosilanes (1)
- pertuzumab (1)
- phylogenetics (1)
- platelet substitution (1)
- ppK − (1)
- proteomics (1)
- pulmonary hypertension (1)
- quorum sensing (1)
- radiation (1)
- radiation-induced nanostructures (1)
- re-transplantation (1)
- reactive systems (1)
- renal failure (1)
- repeated (1)
- respiratorische Infektion (1)
- respiratory infection (1)
- risk stratification (1)
- salivary gland (1)
- silicon nanowires (1)
- site classification system (1)
- small proteins (1)
- specification and verification (1)
- structural biology (1)
- structure–activity relationships (1)
- third (1)
- thrombotic microangiopathy (1)
- thrombotic thrombocytopenic purpura (1)
- trastuzumab (1)
- tumor microenvironment (1)
- vapor–liquid–solid mechanism (1)
- vascular surgery (1)
- verification (1)
- violacein (1)
- von Willebrand factor (1)
- zooplankton (1)
- α-Iminoketones (1)
Institute
Ependymomas encompass a heterogeneous group of central nervous system (CNS) neoplasms that occur along the entire neuroaxis. In recent years, extensive (epi-)genomic profiling efforts have identified several molecular groups of ependymoma that are characterized by distinct molecular alterations and/or patterns. Based on unsupervised visualization of a large cohort of genome-wide DNA methylation data, we identified a highly distinct group of pediatric-type tumors (n = 40) forming a cluster separate from all established CNS tumor types, of which a high proportion were histopathologically diagnosed as ependymoma. RNA sequencing revealed recurrent fusions involving the pleomorphic adenoma gene-like 1 (PLAGL1) gene in 19 of 20 of the samples analyzed, with the most common fusion being EWSR1:PLAGL1 (n = 13). Five tumors showed a PLAGL1:FOXO1 fusion and one a PLAGL1:EP300 fusion. High transcript levels of PLAGL1 were noted in these tumors, with concurrent overexpression of the imprinted genes H19 and IGF2, which are regulated by PLAGL1. Histopathological review of cases with sufficient material (n = 16) demonstrated a broad morphological spectrum of tumors with predominant ependymoma-like features. Immunohistochemically, tumors were GFAP positive and OLIG2- and SOX10 negative. In 3/16 of the cases, a dot-like positivity for EMA was detected. All tumors in our series were located in the supratentorial compartment. Median age of the patients at the time of diagnosis was 6.2 years. Median progression-free survival was 35 months (for 11 patients with data available). In summary, our findings suggest the existence of a novel group of supratentorial neuroepithelial tumors that are characterized by recurrent PLAGL1 fusions and enriched for pediatric patients.
Simple Summary: Acute myeloid leukemia (AML) is a genetically heterogeneous disease. Clinical phenotypes of frequent mutations and their impact on patient outcome are well established. However, the role of rare mutations often remains elusive. We retrospectively analyzed 1529 newly diagnosed and intensively treated AML patients for mutations of BCOR and BCORL1. We report a distinct co-mutational pattern that suggests a role in disease progression rather than initiation, especially affecting mechanisms of DNA-methylation. Further, we found loss-of-function mutations of BCOR to be independent markers of poor outcomes in multivariable analysis. Therefore, loss-of-function mutations of BCOR need to be considered for AML management, as they may influence risk stratification and subsequent treatment allocation.
Abstract: Acute myeloid leukemia (AML) is characterized by recurrent genetic events. The BCL6 corepressor (BCOR) and its homolog, the BCL6 corepressor-like 1 (BCORL1), have been reported to be rare but recurrent mutations in AML. Previously, smaller studies have reported conflicting results regarding impacts on outcomes. Here, we retrospectively analyzed a large cohort of 1529 patients with newly diagnosed and intensively treated AML. BCOR and BCORL1 mutations were found in 71 (4.6%) and 53 patients (3.5%), respectively. Frequently co-mutated genes were DNTM3A, TET2 and RUNX1. Mutated BCORL1 and loss-of-function mutations of BCOR were significantly more common in the ELN2017 intermediate-risk group. Patients harboring loss-of-function mutations of BCOR had a significantly reduced median event-free survival (HR = 1.464 (95%-Confidence Interval (CI): 1.005–2.134), p = 0.047), relapse-free survival (HR = 1.904 (95%-CI: 1.163–3.117), p = 0.01), and trend for reduced overall survival (HR = 1.495 (95%-CI: 0.990–2.258), p = 0.056) in multivariable analysis. Our study establishes a novel role for loss-of-function mutations of BCOR regarding risk stratification in AML, which may influence treatment allocation.
Background and Objectives: Proteins of the coagulation system contribute to autoimmune inflammation in patients with multiple sclerosis (MS). On blood-brain barrier (BBB) disruption, fibrinogen enters the CNS and is rapidly converted to fibrin, unfolding pleiotropic autoimmune mechanisms. Fibrin accumulation leads to subsequent proteolytic degradation that results in D-dimer generation. The primary objective of this study was to determine intrathecal levels of D-dimer in CSF as a measure of intrathecal coagulation cascade activation and to evaluate its diagnostic utility in patients with MS in contrast to healthy subjects. Key secondary objectives included analysis of CSF D-dimer in differential diagnoses of MS and its relation to routine clinical markers of disease activity.
Methods: Patients admitted for the assessment of suspected MS were prospectively recruited from October 2017 to December 2020. Blood plasma and citrated CSF samples were analyzed using a highly sensitive luminescent oxygen channeling immunoassay. Intrathecal generation of D-dimer was analyzed by adjusting for CSF/serum albumin (Qalb) and CSF/plasma D-dimer quotients (QD-dimer), and corresponding CSF fibrinogen levels were determined. Final diagnoses after full evaluation and clinical data were recorded.
Results: Of 187 patients, 113 patients received a diagnosis of MS or clinically/radiologically isolated syndrome. We found increased intrathecal CSF D-dimer generation levels (QD-dimer/Qalb-index) for patients with relapsing-remitting MS (RRMS; n = 71, median 4.7, interquartile range [IQR] 2.5–8.0) when compared with those for disease controls (n = 22, median 2.6, IQR 2.1–4.8, p = 0.031). Absolute CSF D-dimer values correlated with CSF fibrinogen levels (r = 0.463; p < 0 .001) and CSF leukocytes (r = 0.273; p = 0.003) and were elevated in MS patients with contrast enhancement (CE) compared with MS patients without CE on MRI (n = 48, median 6 ng/mL, and IQR 3–15.25 vs n = 41, median 4 ng/mL, and IQR 2–7; p = 0.026). Exploratory subgroup analyses indicated a correlation of intrathecal inflammatory activity and CSF D-dimer levels.
Discussion: D-dimer in CSF can be reliably determined and correlates with markers of CNS inflammation and CSF fibrinogen levels. Adjusted for BBB dysfunction, CSF D-dimer may allow the identification of intrathecal coagulation cascade activation in patients with MS.
Classification of Evidence: This study provides Class I evidence that CSF D-dimer levels are elevated in patients with RRMS.
Objective: The objective of this study was to describe and analyze the effects of depression on health care utilization and costs in a sample of multimorbid elderly patients.
Method: This cross-sectional analysis used data of a prospective cohort study, consisting of 1,050 randomly selected multimorbid primary care patients aged 65 to 85 years. Depression was defined as a score of six points or more on the Geriatric Depression Scale (GDS-15). Subjects passed a geriatric assessment, including a questionnaire for health care utilization. The impact of depression on health care costs was analyzed using multiple linear regression models. A societal perspective was adopted.
Results: Prevalence of depression was 10.7%. Mean total costs per six-month period were €8,144 (95% CI: €6,199-€10,090) in patients with depression as compared to €3,137 (95% CI: €2,735-€3,538; p<0.001) in patients without depression. The positive association between depression and total costs persisted after controlling for socio-economic variables, functional status and level of multimorbidity. In particular, multiple regression analyses showed a significant positive association between depression and pharmaceutical costs.
Conclusion: Among multimorbid elderly patients, depression was associated with significantly higher health care utilization and costs. The effect of depression on costs was even greater than reported by previous studies conducted in less morbid patients.
Die Flechte Cladonia stygia (Fr.) Ruoss wurde anlässlich einer Bestandsaufnahme der Rentierflechten 2009 erstmals aus Hessen gemeldet. Da die Unterscheidung von der ähnlichen C. rangiferina (L.) F. H. Wigg. anhand morphologischer Merkmale oft unsicher ist, wurden molekulargenetische Daten zur Identifizierung der hessischen Belege der Art herangezogen. Phylogenetische Stammbäume auf der Grundlage von sechs mitochondrialen und nuklearen Genloci untermauern die Abgrenzung beider Arten. Nur zwei von sieben gemeldeten hessischen Vorkommen gehören nach diesen Ergebnissen zu C. stygia, die übrigen zu C. rangiferina. Eine gezielte Suche nach C. stygia und eine durch molekulargenetische Daten untermauerte Bestimmung der Belege erscheint notwendig, um den Status der Art in Hessen zuverlässig beurteilen zu können.